User profiles for A. Nirula

Ajay Nirula

Verified email at oski.com
Cited by 7726

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

A Nirula, J Nilsen, P Klekotka, G Kricorian… - …, 2016 - academic.oup.com
IL-17 cytokines are expressed by a variety of cells and mediate host defence against extracellular
pathogens. IL-17 is upregulated at sites of inflammation and can synergize with other …

What is IgG4? A review of the biology of a unique immunoglobulin subtype

A Nirula, SM Glaser, SL Kalled… - Current opinion in …, 2011 - journals.lww.com
Nirula, Ajay a ; Glaser, Scott M a ; Kalled, Susan L b ; Taylora, Frederick R b …
Correspondence to Ajay Nirula, Biogen Idec, 5200 Research Place, San Diego, CA 92130, USA …

[HTML][HTML] Bamlanivimab plus etesevimab in mild or moderate Covid-19

M Dougan, A Nirula, M Azizad… - … England Journal of …, 2021 - Mass Medical Soc
Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, …

[HTML][HTML] SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

P Chen, A Nirula, B Heller, RL Gottlieb… - … England Journal of …, 2021 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-…

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

RL Gottlieb, A Nirula, P Chen, J Boscia, B Heller… - Jama, 2021 - jamanetwork.com
Nirula had full access to all of the data in the study and take responsibility for the integrity of
the data and the accuracy of the data analysis. Drs Gottlieb and Nirula … Drs Nirula and Adams…

[HTML][HTML] Phase 3 studies comparing brodalumab with ustekinumab in psoriasis

…, N Erondu, P Klekotka, B Kotzin, A Nirula - … England Journal of …, 2015 - Mass Medical Soc
Background Early clinical studies suggested that the anti–interleukin-17 receptor A monoclonal
antibody brodalumab has efficacy in the treatment of psoriasis. Methods In two phase 3 …

[HTML][HTML] Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

…, JY Feng, N Erondu, A Nirula - … England Journal of …, 2014 - Mass Medical Soc
Background We assessed the efficacy and safety of brodalumab, a human monoclonal
antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, …

[HTML][HTML] Gene editing and crop improvement using CRISPR-Cas9 system

L Arora, A Narula - Frontiers in plant science, 2017 - frontiersin.org
Advancements in Genome editing technologies have revolutionized the fields of functional
genomics and crop improvement. CRISPR/Cas9 (clustered regularly interspaced short …

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

…, NL Byers, DE Schlichting, A Nirula… - EMBO molecular …, 2020 - embopress.org
Baricitinib is an oral Janus kinase ( JAK )1/ JAK 2 inhibitor approved for the treatment of
rheumatoid arthritis ( RA ) that was independently predicted, using artificial intelligence ( AI ) …

Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial

MS Cohen, A Nirula, MJ Mulligan, RM Novak… - Jama, 2021 - jamanetwork.com
Importance Preventive interventions are needed to protect residents and staff of skilled
nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. …